Federal Register / Vol. 72, No. 44 / Wednesday, March 7, 2007 / Notices 10219 

Form name & 

number (CFR 

reference) 

Respondents Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per respondent 

(in hours) 

Total burden 

(in hours) 

83.9 ................... Petitioners using Form A ................................................ 30 1 3/60 1 .5 

83.9 ................... Petitioners using Form B ................................................ 40 1 5 200 

83.9 ................... Petitioners not using Form B .......................................... 5 1 5.5 27 .5 

83.18 ................. Petitioners Appealing proposed decisions ..................... 5 1 45/60 3 .75 

Total .......... ......................................................................................... 80 ........................ ........................ 233 

Dated: February 28, 2007. 

Joan F. Karr, 

Acting Reports Clearance Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. E7–3985 Filed 3–6–07; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60-Day 07–07AN] 

Proposed Data Collections Submitted 

for Public Comment and 

Recommendations 

In compliance with the requirement 

of Section 3506(c)(2)(A) of the 

Paperwork Reduction Act of 1995 for 

opportunity for public comment on 

proposed data collection projects, the 

Centers for Disease Control and 

Prevention (CDC) will publish periodic 

summaries of proposed projects. To 

request more information on the 

proposed projects or to obtain a copy of 

the data collection plans and 

instruments, call 404–639–5960 and 

send comments to Joan Karr, CDC 

Acting Reports Clearance Officer, 1600 

Clifton Road, MS–D74, Atlanta, GA 

30333 or send an e-mail to 

omb@cdc.gov. 

Comments are invited on: (a) Whether 

the proposed collection of information 

is necessary for the proper performance 

of the functions of the agency, including 

whether the information shall have 

practical utility; (b) the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information; (c) 

ways to enhance the quality, utility, and 

clarity of the information to be 

collected; and (d) ways to minimize the 

burden of the collection of information 

on respondents, including through the 

use of automated collection techniques 

or other forms of information 

technology. Written comments should 

be received within 60 days of this 

notice. 

Proposed Project 

Program Effectiveness Evaluation of 

Workplace Intervention for Intimate 

Partner Violence (IPV)—New—National 

Center for Injury Prevention and 

Control, Centers for Disease Control and 

Prevention (CDC). 

Background and Brief Description 

Intimate partner violence (IPV) affects 

a substantial number of Americans, and 

there has recently been increasing 

recognition of the impact it has on the 

workplace. In addition to direct impacts 

(batterers often stalk or even attack IPV 

victims at their place of work), IPV has 

indirect impacts on the workplace 

environment through lost productivity 

due to medical leave, absenteeism, and 

fear and distraction on the part of 

victims and coworkers. The Centers for 

Disease Control and Prevention (CDC) 

has employed contractor support to 

evaluate an ongoing workplace IPV 

prevention program being implemented 

at a national corporation. The purpose 

of the proposed evaluation is to 

document in detail the workplace IPV 

prevention activities delivered by the 

company, to determine the impact of 

these activities on short-term and longterm outcomes, and to determine the 

cost-effectiveness of the program. All 

managers at the corporation will be 

screened to assess training experiences. 

Then, more in-depth surveys will be 

done among managers who have not 

had the corporation’s IPV training. We 

will survey those 500 managers at 

baseline, and 6 and 12 months later. 

Manager surveys will focus on 

knowledge/awareness of IPV and 

company resources for IPV and number 

of referrals for IPV assistance. We will 

also survey employees of those 

managers using an anonymous webbased survey at baseline and 12 months 

later to assess their self-evaluated 

productivity, absenteeism, and 

perceptions of manager behavior. We 

will compare the responses of managers 

(and their employees) who received the 

IPV training in the study period (i.e., 

sometime between the baseline and 12 

month surveys) with untrained 

managers. The study will provide CDC 

and employers information about the 

potential effectiveness and costeffectiveness of workplace IPV 

intervention strategies. 

There are no costs to respondents 

except their time to participate in the 

interview. 

ESTIMATE OF ANNUALIZED BURDEN HOURS

Respondents Number of respondents 

Number of responses per 

respondent 

Average burden per response 

(in hours) 

Total burden 

(in hours) 

Employee ......................................................................................................... 1500 2 30/60 1500 

Manager ........................................................................................................... 500 3 30/60 75 

Total .......................................................................................................... 2000 ........................ ........................ 2250 


sroberts on PROD1PC70 with NOTICES
10220 Federal Register / Vol. 72, No. 44 / Wednesday, March 7, 2007 / Notices 

Dated: February 28, 2007. 

Joan F. Karr, 

Acting Reports Clearance Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. E7–3986 Filed 3–6–07; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Statement of Organization, Functions 

and Delegation of Authority; 

Republication 

Editorial Note: FR Doc. E7–3306 originally 

published at page 8742 in the issue of 

Tuesday, February 27, 2007. The original 

publication contained erroneous text. As a 

result, the corrected document is being 

republished in its entirety. 

Notice is hereby given that I have 

delegated to the Director, Office of Head 

Start, the following authority vested in 

me by the Secretary of Health and 

Human Services in a memorandum 

dated August 20, 1991, pertaining to the 

Head Start Program and the Child 

Development Associate Scholarship 

Assistance Grants Program. 

(a) Authority Delegated 

Authority to administer the Head 

Start Program under the Head Start Act, 

42 U.S.C. 9801 et seq., and as amended 

now and hereafter. (This includes 

authority to administer the Early Head 

Start program.) 

(b) Limitations 

1. This delegation of authority shall 

be exercised under the Department’s 

existing policies on delegations and 

regulations. 

2. This delegation of authority does 

not include the authority to submit 

reports to Congress and shall be 

exercised under financial and 

administrative requirements applicable 

to all Administration for Children and 

Families’ authorities. 

3. The approval or disapproval of 

grant applications including refunding 

applications, the making of grant 

awards, the waiver of non-Federal share 

under 42 U.S.C. 9835(b), the waiver of 

fifteen percent administrative cost 

limitations under 42 U.S.C. 9839(b), and 

the approval of interim grantees under 

42 U.S.C. 9836(e) requires concurrence 

of the appropriate Grants Officer. The 

approval or disapproval of contract 

proposals and awards is subject to the 

requirements of the Federal Acquisition 

Regulations and requires the 

concurrence of the Contracting Officer. 

4. This delegation of authority does 

not include the authority to approve or 

disapprove awards for grants or 

contracts for research, demonstration, or 

evaluation under section 649 of the 

Head Start Act. 

5. This delegation of authority does 

not include the authority to appoint 

Central Office or Regional Office Grant 

Officers for the administration of the 

Head Start Program. 

6. This delegation of authority does 

not include the authority to appoint 

Action Officials for Audit Resolution. 

7. This delegation of authority does 

not include the authority to sign and 

issue notices of grant awards. 

8. This delegation of authority does 

not include the authority to hold 

hearings. This limitation does not 

include the ‘‘informal meetings’’

authorized in 45 CFR part 1303. 

9. Any redelegation shall be in writing 

and prompt notification must be 

provided to all affected managers, 

supervisors, and other personnel, and 

requires the concurrence of the Deputy 

Assistant Secretary for Administration. 

(c) Effect on Existing Delegations 

As related to this delegation of 

authority, this delegation supersedes all 

previous delegations of authority 

involving the Head Start Program except 

the September 25, 2002, delegation to 

the Director, Office of Planning, 

Research and Evaluation relating to 

section 649 of the Head Start Act. 

(d) Effective Date 

This delegation is effective upon the 

date of signature. 

I hereby affirm and ratify any actions 

taken by the Director, Office of Head 

Start, which involved the exercise of the 

authority delegated herein prior to the 

effective date of this delegation. 

Dated: February 16, 2007. 

Wade F. Horn, 

Assistant Secretary for Children and Families. 

[FR Doc. E7–3306 Filed 2–26–07; 8:45 am] 

Editorial Note: FR Doc. E7–3306 originally 

published at page 8742 in the issue of 

Tuesday, February 27, 2007. The original 

publication contained erroneous text. As a 

result, the corrected document is being 

republished in its entirety. 

[FR Doc. R7–3306 Filed 3–6–07; 8:45 am] 

BILLING CODE 1505–01–D 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. 2006N–0036] 

Agency Information Collection 

Activities; Submission for Office of 

Management and Budget Review; 

Comment Request; Experimental 

Study of Possible Footnotes and 

Cueing Schemes to Help Consumers 

Interpret Quantitative Trans Fat 

Disclosure on the Nutrition Facts Panel 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing 

that a proposed collection of 

information has been submitted to the 

Office of Management and Budget 

(OMB) for review and clearance under 

the Paperwork Reduction Act of 1995. 

DATES: Fax written comments on the 

collection of information by April 6, 

2007. 

ADDRESSES: To ensure that comments on 

the information collection are received, 

OMB recommends that written 

comments be faxed to the Office of 

Information and Regulatory Affairs, 

OMB, Attn: FDA Desk Officer, FAX: 

202–395–6974. 

FOR FURTHER INFORMATION CONTACT: 

Jonna Capezzuto, Office of the Chief 

Information Officer (HFA–250), Food 

and Drug Administration, 5600 Fishers 

Lane, Rockville, MD 20857, 301–827–

4659. 

SUPPLEMENTARY INFORMATION: In 

compliance with 44 U.S.C. 3507, FDA 

has submitted the following proposed 

collection of information to OMB for 

review and clearance. In the Federal 

Register of December 18, 2006 (71 FR 

75762), FDA published a notice entitled 

‘‘Agency Information Collection 

Activities; Submission for Office of 

Management and Budget Review; 

Comment Request; Experimental Study 

of Possible Footnotes and Cueing 

Schemes to Help Consumers Interpret 

Quantitative Trans Fat Disclosure on the 

Nutrition Facts Panel.’’ This notice 

contained an incorrect deadline for 

comments on the proposed collection of 

information in the DATES section. FDA 

is republishing the notice and providing 

a full 30-day comment period. Any 

comments previously submitted 

regarding this notice will be considered 

and do not need to be re-submitted. 


sroberts on PROD1PC70 with NOTICES